文献速递产科

美国回顾性队列研究:缩宫素用于加强宫缩与产后出血无关

Oxytocin is not associated with postpartum hemorrhage in labor augmentation in a retrospective cohort study in the United States.
PubMed 文献 · Am J Obstet Gynecol · 2023-08-03

该研究基于美国犹他州Intermountain Healthcare 20,899例足月、头位、单胎、自然临产且无剖宫产史孕妇的数据,采用倾向性评分及加权广义可加混合模型控制产程模式等混杂因素,评估缩宫素加强宫缩与产后出血的独立关联。结果显示,在严格控制产程模式和潜在混杂因素后,缩宫素加强宫缩与估计失血量(6.5 mL;95%CI 2.5-10.3)或产后出血(调整OR 1.02;95%CI 0.82-1.24)均无临床或统计学显著关联。

要点

  • 缩宫素加强宫缩与产后出血无显著关联(调整OR 1.02;95%CI 0.82-1.24)。
  • 缩宫素加强宫缩与估计失血量无显著关联(6.5 mL;95%CI 2.5-10.3)。
  • 随着缩宫素加强宫缩的持续时间和总剂量增加,产后出血和估计失血量的比值比适度增加。

核心结论

  • 在严格控制产程模式和潜在混杂因素后,缩宫素加强宫缩与估计失血量或产后出血风险无临床显著关联。
  • 随着缩宫素加强宫缩的持续时间和总剂量增加,产后出血和估计失血量的比值比适度增加。

研究设计与样本

  • 回顾性队列研究,数据来自美国犹他州Intermountain Healthcare的Consortium on Safe Labor。
  • 纳入20,899例足月、头位、单胎、自然临产且无剖宫产史的孕妇。
  • 采用倾向性评分、协变量平衡广义倾向性评分及逆概率加权评估缩宫素加强宫缩与产后出血的关联。

主要发现

  • 与未使用缩宫素的女性相比,缩宫素加强宫缩与估计失血量无临床或统计学显著关联(6.5 mL;95%CI 2.5-10.3)。
  • 与未使用缩宫素的女性相比,缩宫素加强宫缩与产后出血无临床或统计学显著关联(调整OR 1.02;95%CI 0.82-1.24)。
  • 无论是否纳入产时剖宫产的女性,结果保持一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies reported conflicting results on the relationship between oxytocin use for labor augmentation and the risk of postpartum hemorrhage, probably because it is rather challenging to disentangle oxytocin use from labor dystocia. OBJECTIVE: This study aimed to investigate the independent association between oxytocin use for augmentation and the risk of postpartum hemorrhage by using advanced statistical modeling to control for labor patterns and other covariates. STUDY DESIGN: We used data from 20,899 term, cephalic, singleton pregnancies of patients with spontaneous onset of labor and no previous cesarean delivery from Intermountain Healthcare in Utah in the Consortium on Safe Labor. Presence of postpartum hemorrhage was identified on the basis of a clinical diagnosis. Propensity scores were calculated using a generalized linear mixed model for oxytocin use for augmentation, and covariate balancing generalized propensity score was applied to obtain propensity scores for the duration and total dosage of oxytocin augmentation. A weighted generalized additive mixed model was used to depict dose-response curves between the duration and total dosage of oxytocin augmentation and the outcomes. The average treatment effects of oxytocin use for augmentation on postpartum hemorrhage and estimated blood loss (mL) were assessed by inverse probability weighting of propensity scores. RESULTS: The odds of both postpartum hemorrhage and estimated blood loss increased modestly when the duration and/or total dosage of oxytocin used for augmentation increased. However, in comparison with women for whom oxytocin was not used, oxytocin augmentation was not clinically or statistically significantly associated with estimated blood loss (6.5 mL; 95% confidence interval, 2.5-10.3) or postpartum hemorrhage (adjusted odds ratio, 1.02; 95% confidence interval, 0.82-1.24) when rigorously controlling for labor pattern and potential confounders. The results remained consistent regardless of inclusion of women with an intrapartum cesarean delivery. CONCLUSION: The odds of postpartum hemorrhage and estimated blood loss increased modestly with increasing duration and total dosage of oxytocin augmentation. However, in comparison with women for whom oxytocin was not used and after controlling for potential confounders, there was no clinically significant association between oxytocin use for augmentation and estimated blood loss or the risk of postpartum hemorrhage.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zhu H, Lu D, Branch DW, et al. Oxytocin is not associated with postpartum hemorrhage in labor augmentation in a retrospective cohort study in the United States. Am J Obstet Gynecol. 2023. PMID: 37541482. doi:10.1016/j.ajog.2023.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。